Dr. Porter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
461 Timber Ln
Devon, PA 19333Phone+1 610-989-3767
Education & Training
- University of California (San Francisco)Residency, Neurology, 1971 - 1974
- University of California (San Diego) Medical CenterInternship, Internal Medicine, 1968 - 1969
- Duke University School of MedicineClass of 1968
- Eckerd CollegeBS, 1960 - 1964
Certifications & Licensure
- PA State Medical License 1992 - 2022
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Lifetime Accelerator Award Epilepsy Foundation, 2015
- Service Award American Epilepsy Society, 2014
- Doctor of Science (Hon) Eckerd College, 2008
- Join now to see all
Publications & Presentations
PubMed
- 502 citationsAntiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds.Michael A. Rogawski, Roger J. Porter
Pharmacological Reviews. 1990-09-01 - 6 citationsEfficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.Jacqueline A French, Roger J Porter, Emilio Perucca, Martin J Brodie, Michael A Rogawski
JAMA Neurology. 2023-11-01 - 71 citationsElectroencephalographic studies of simple partial seizures with subdural electrode recordings.O. Devin sky, Susumu Sato, Conrad V. Kufta, B. Ito, Douglas F. Rose
Neurology. 1989-04-01
Journal Articles
- The Epilepsy Foundation's 4th Biennial Epilepsy Pipeline Update ConferenceFrench JA, Schachter SC, Sirven J and Porter RJ., Epilepsy and Behavior, 1/1/2015
- Mechanisms of action of anti-seizure drugs and the anticonvulsant screening program of the National Institute of Neurological Disorders and StrokePorterRJ, Kupferberg HJ and Hessie BJ, International Journal of Clinical Pharmacology and Therapeutics, 1/1/2015
- A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical developmentSachdeo R, Partiot A, Biton V, Rosenfeld WE, Nohria V, Tompson D, DeRossett S, and PorterRJ, International Journal of Clinical Pharmacology and Therapeutics, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Long-term maintenance of efficacy with ezogabine (retigabine) 600-1200mg/day: an assessment of three open-label extension studies over 12 monthsBurdette DE, Porter RJ, Lee WK, Hall ST, DeRossett SE, Neurology, 1/1/2011
- Dose titration and dosing regimen for retigabine as adjunctive therapy in adults with refractory epilepsy with partial-onset seizures.Gil-Nagel A, Abou-Khalil B, Porter R, Hall S, Hammond J, VanLandingham K, Eur J Neurol., 1/1/2010
- Efficacy of retigabine 600-1200 mg/day in patients with refractory epilepsy with partial-onset seizures: integrated analysis of three randomized studiesPorter RJ, French JA, Brodie MJ, VanLandingham KE, Nanry KP, Hall ST, Neurology, 1/1/2010
- Join now to see all
Lectures
- The future of epilepsy researchNew Dehli - 1/1/1989
- Social aspects of epilepsyWashington, DC - 1/1/1976
- Quantitation of paroxysmal abnormal discharge in the EEGs of patients with absence (petit mal) seizures for evaluation of antiepileptic drugsNew York, NY - 1/3./1971
- Join now to see all
Other
- Epilepsy, Antiepileptic Drugs, (CD only)Encyclopedia of Neuroscience
1/1/2004 - Antiepileptic DrugsPorter RJ, Encyclopedia of Neuroscience, CD Rom
Boston - 1/1/1998 - Medicine for the Layman: EpilepsyPorter RJ, NIH
1/1/1982 - Join now to see all
Press Mentions
- Novel Treatment Options for EpilepsyMay 7th, 2024
External Links
- Roger J. Porter, MD, LLChttp://www.rjportermd.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: